According to a new report, published by KBV research, The Global Dementia Treatment Market size is expected to reach $29.2 billion by 2031, rising at a market growth of 7.4% CAGR during the forecast period.
The Diagnosis segment is leading the Dementia Treatment Market by Type in 2023; thereby, achieving a market value of $12.8 billion by 2031. The segment's expansion can be characterized by the growing emphasis on the early detection and precise diagnosis of dementia-related conditions, which is essential for the timely intervention and management of these conditions. Diagnostic tools and techniques, such as cognitive assessments, neuroimaging, and biomarker analysis, play a vital role in identifying dementia and differentiating it from other cognitive disorders, contributing to the diagnosis segment's dominance in the market.
The Injectable segment is experiencing a CAGR of 7% during (2024 - 2031). In situations where oral administration is impossible or ineffective, injectable formulations of dementia drugs, including long-acting antipsychotics and disease-modifying therapies, are used. Injectable medications offer the advantage of bypassing the gastrointestinal tract, ensuring rapid absorption and consistent drug levels in the bloodstream. These formulations are often used in severe cases of dementia or when oral medications are not well-tolerated, contributing to their significant share in the market.
The Hospital Pharmacy segment is generating the maximum revenue in the Global Dementia Treatment Market by Dementia Drugs Distribution Channel in 2023; thereby, achieving a market value of $10.3 billion by 2031. Hospital pharmacies are crucial in providing access to specialized medications and treatments for dementia patients who require inpatient or outpatient care. These pharmacies frequently maintain an extensive inventory of dementia medications and possess the necessary skills to oversee intricate medication regimens, which has facilitated their market dominance.
The Lewy Body Dementia segment is registering a CAGR of 8.9% during (2024 - 2031). Lewy body dementia is the second most common form of progressive dementia after Alzheimer's disease, characterized by abnormal protein deposits in the brain. Managing Lewy body dementia involves a multidisciplinary approach, including pharmacological and non-pharmacological interventions, contributing to this market segment's substantial share.
Full Report: https://www.kbvresearch.com/dementia-treatment-market/
The North America region dominated the Global Dementia Treatment Market by Region in 2023; thereby, achieving a market value of $11 billion by 2031. The Europe region is poised to grow at a CAGR of 7% during (2024 - 2031). Additionally, The Asia Pacific region would witness a CAGR of 8% during (2024 - 2031).
By Type
By Dementia Drugs Route of Administration
By Dementia Drugs Distribution Channel
By Indication
By Geography
Unique Offerings 
